Larry Dillaha
Chief Tech/Sci/R&D Officer bei NUTRIBAND INC.
Profil
Larry M.
Dillaha currently works at Melt Pharmaceuticals, Inc., as Chief Executive Officer & Director from 2021, New Haven Pharmaceuticals, Inc., as Chief Medical Officer & Executive VP-Operations from 2014, and Nutriband, Inc., as Chief Medical Officer from 2018.
Dr. Dillaha also formerly worked at Repros Therapeutics, Inc., as President, Chief Executive Officer & Director from 2017 to 2018, Cavtherx, Inc., as Chief Executive Officer & Director from 2016 to 2017, Baptist Hospital (Tennessee), as Medical Director from 2000 to 2002, Sanofi-Aventis U.S.
LLC, as Medical Director in 2006, Sanofi-Synthelabo, Inc., as Medical Director-Cardiovascular from 2002 to 2006, Shionogi Pharma, Inc., as Chief Medical Officer from 2006 to 2010, Shionogi & Co., Ltd., as Chief Medical Officer & Executive Vice President, Harrow, Inc., as Chief Medical Officer, and INSYS Therapeutics, Inc., as Chief Medical Officer from 2011 to 2014.
Dr. Dillaha received his undergraduate degree and doctorate degree from the University of Tennessee.
Aktive Positionen von Larry Dillaha
| Unternehmen | Position | Beginn |
|---|---|---|
| NUTRIBAND INC. | Chief Tech/Sci/R&D Officer | 02.08.2018 |
New Haven Pharmaceuticals, Inc.
 New Haven Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology New Haven Pharmaceuticals, Inc. develops new prescription drug products. It developes proprietary prescription pharmaceuticals that utilize currently marketed drugs or generally recognized as safe (GRAS) active pharmaceutical ingredients (APIs) for use in therapeutic applications. The company was founded by Harry H. Penner Jr. in 2008 and is headquartered in Branford, CT. | Chief Operating Officer | - |
Melt Pharmaceuticals, Inc.
 Melt Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Melt Pharmaceuticals, Inc. engages in the development and commercialization of proprietary non-opioid, non-intravenous, or non-IV, sedation and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings. It intends to seek regulatory approval through the FDA regulatory pathway for the proprietary, patented small-molecule product candidates. The company was founded by Mark L. Baum on April 3, 2018 and is headquartered in Brentwood, TN. | Chief Executive Officer | 01.06.2021 |
Ehemalige bekannte Positionen von Larry Dillaha
| Unternehmen | Position | Ende |
|---|---|---|
| HARROW, INC. | Chief Tech/Sci/R&D Officer | 01.01.2021 |
| REPROS THERAPEUTICS INC | Chief Executive Officer | 01.02.2018 |
Cavtherx, Inc.
 Cavtherx, Inc. Miscellaneous Commercial ServicesCommercial Services Cavtherx, Inc. provides biological research services. The private company is based in New Haven. | Chief Executive Officer | 01.02.2017 |
| INSYS THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 11.05.2014 |
Shionogi Pharma, Inc.
 Shionogi Pharma, Inc. Pharmaceuticals: MajorHealth Technology Shionogi Pharma, Inc. manufactures pharmaceuticals. The company is headquartered in Alpharetta, GA. | Chief Tech/Sci/R&D Officer | 01.03.2010 |
Ausbildung von Larry Dillaha
| University of Tennessee | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| SHIONOGI & CO., LTD. | Health Technology |
| HARROW, INC. | Health Technology |
| NUTRIBAND INC. | Health Technology |
| Private Unternehmen | 9 |
|---|---|
Repros Therapeutics, Inc.
 Repros Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Repros Therapeutics, Inc. is a development stage biopharmaceutical company, which focuses on the development of drugs to treat hormonal and reproductive systems disorders. Its products include Enclomiphene and Proellex. The company was founded on August 20, 1987 and is headquartered in The Woodlands, TX. | Health Technology |
Shionogi Pharma, Inc.
Shionogi Pharma, Inc. Pharmaceuticals: MajorHealth Technology Shionogi Pharma, Inc. manufactures pharmaceuticals. The company is headquartered in Alpharetta, GA. | Health Technology |
Baptist Hospital (Tennessee)
 Baptist Hospital (Tennessee) Hospital/Nursing ManagementHealth Services Baptist Hospital (Tennessee) provides healthcare services. The company offers services in the areas of cancer, cardiac, and diabetes. Its services include rehabilitation and childbirth services. Baptist Hospital was founded in 1918 and is headquartered in Nashville, TN. | Health Services |
Sanofi-Aventis U.S. LLC
 Sanofi-Aventis U.S. LLC Pharmaceuticals: MajorHealth Technology Sanofi-Aventis U.S. LLC engages in the provision of pharmaceutical products. It discovers, develops, produces and markets innovative therapies. The firm extensive research and development efforts are focused on health care challenges in cardiology, oncology and internal medicine, as well as metabolic diseases, central nervous system disorders, ophthalmology and vaccines. The company is headquartered in Bridgewater, NJ. | Health Technology |
| Sanofi-Synthelabo, Inc. | Health Technology |
New Haven Pharmaceuticals, Inc.
New Haven Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology New Haven Pharmaceuticals, Inc. develops new prescription drug products. It developes proprietary prescription pharmaceuticals that utilize currently marketed drugs or generally recognized as safe (GRAS) active pharmaceutical ingredients (APIs) for use in therapeutic applications. The company was founded by Harry H. Penner Jr. in 2008 and is headquartered in Branford, CT. | Health Technology |
INSYS Therapeutics, Inc.
 INSYS Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology INSYS Therapeutics, Inc. operates as a pharmaceutical company, which develops and commercializes supportive care products. It focuses on utilizing commercial pharmaceutical products that include Subsys, a proprietary sublingual fentanyl spray for BTCP in opioid-tolerant adult patients; and Syndros, a proprietary orally administered liquid formulation of dronabinol for the treatment of CINV and anorexia associated with weight loss in patients with AIDS. The company was founded by John N. Kapoor on June 15, 1990 and is headquartered in Chandler, AZ. | Health Technology |
Cavtherx, Inc.
Cavtherx, Inc. Miscellaneous Commercial ServicesCommercial Services Cavtherx, Inc. provides biological research services. The private company is based in New Haven. | Commercial Services |
Melt Pharmaceuticals, Inc.
Melt Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Melt Pharmaceuticals, Inc. engages in the development and commercialization of proprietary non-opioid, non-intravenous, or non-IV, sedation and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings. It intends to seek regulatory approval through the FDA regulatory pathway for the proprietary, patented small-molecule product candidates. The company was founded by Mark L. Baum on April 3, 2018 and is headquartered in Brentwood, TN. | Health Technology |
